Gilead's Remdesivir allowed being administrated to hospitalized patients
Good news came from the American continent. One major pharma
company got the Food and Drug Administration approval for its COVID-19 vaccine.
The California-based company, Gilead, announced that
the FDA green-lit the antiviral medicine Remdesivir to be given to hospitalized
patients.
Remdesivir, which is the same drug that President Trump was
given after testing positive for COVID-19 infection, will be sold under the
name Veklury.
Veklury is now the first and only approved Covid-19
treatment in the United States," said Gilead. However, the World
Health Organization released a statement earlier this year that showed the
drug's inefficiency to reduce the number of deaths caused by the virus.
After the news hit the wire, Gilead's stock price went up
0.76%.
Sources: thestreet.com
This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.
Previous Article
Chipotle showed resilience in Q3
Next Article
Samsung’s chairman dies, shares go up after the news